EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukemia

Subazini Thankaswamy Kosalai,Mohammad Hamdy Abdelrazak Morsy,Nikos Papakonstantinou,Larry Mansouri,Niki Stavroyianni,Chandrasekhar Kanduri,Kostas Stamatopoulos,Richard Rosenquist,Meena Kanduri

EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukemia

2019

Subazini Thankaswamy Kosalai
Mohammad Hamdy Abdelrazak Morsy
Nikos Papakonstantinou
Larry Mansouri
Niki Stavroyianni
Chandrasekhar Kanduri
Kostas Stamatopoulos
Richard Rosenquist
Meena Kanduri

ABSTRACTEZH2 is overexpressed in poor-prognostic chronic lymphocytic leukaemia (CLL) cases, acting as an oncogene; however, thus far, the EZH2 target genes in CLL have not been disclosed. In this s...

Keywords:

Cancer research
Chronic lymphocytic leukemia
PI3K/AKT/mTOR pathway
Insulin-like growth factor 1 receptor
Molecular biology
EZH2
Biology
Oncogene
ChIP-sequencing
Gene
Lymphocytic leukaemia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations